Bax Protein in Cancer Treatment

Jin-Hyuk Choi

doi:10.5124/jkma.2007.50.11.1016

Journal List > J Korean Med Assoc > v.50(11) > 1041839

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Choi: Bax Protein in Cancer Treatment

Continuing Education Column

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2007; 50(11): 1016-1022.

Published online: 30 November 2007

DOI: https://doi.org/10.5124/jkma.2007.50.11.1016

Bax Protein in Cancer Treatment

Jin-Hyuk Choi, MD

Department of Hematology-Oncology, Ajou University College of Medicine, Korea. jhchoimd@ajou.ac.kr

Abstract

Apoptosis is the major mechanism of cancer cell death by chemotherapy as well as radiation. Bax is a critical downstream mediator of apoptosis which belonged to the Bcl-2 family, and it initiates a mitochondrial permeability shift transition, leading to the activation of downstream apoptosis signaling pathways. Bax protein is activated by BH3-only proteins or p53, while prosurvival Bcl-2 family proteins suppress the function of Bax protein. Therefore, genetic defects in Bax may not only result in intrinsic biologic aggressiveness but also cause resistance to the cytotoxic effects of chemotherapy and radiotherapy. The role of low expression of Bax protein as a poor prognostic or predictive factor has been reported in several malignancies such as breast, colorectal, ovarian, esophageal, and head and neck cancer. Various novel therapeutic approaches targeting Bax protein are under investigation. In addition, several studies suggest that the evaluation of Bax protein with a pretreatment biopsy specimen may provide valuable information to the oncologist for the selection of appropriate therapeutic modality for the patients.

Keywords: Apoptosis, Bax protein, Low expression, Resistance, Prognostic factor

Figures and Tables

Figure 1

Apoptosis signaling pathways.

References

1. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006. 25:4798–4811.

2. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007. 26:1324–1337.

3. Reed JC. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ. 2006. 13:1378–1386.

4. Labi V, Erlacher M, Kiessling S, Villunger A. BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Differ. 2006. 13:1325–1338.

5. Hacker G, Weber A. BH3-only proteins trigger cytochrome c release, but how? Arch Biochem Biophys. 2007. 462:150–155.

6. Zinkel S, Gross A, Yang E. Bcl-2 family in DNA damage and cell cycle control. Cell Death Differ. 2006. 13:1351–1359.

7. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993. 74:609–619.

8. Knudson CM, Tung KS, Tourtellotte WG, Brown GA, Korsmeyer SJ. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science. 1995. 270:96–99.

9. White FA, Keller-Peck CR, Knudson CM, Korsmeyer SJ, Snider WD. Widespread elimination of naturally occurring neuronal death in Bax-deficient mice. J Neurosci. 1998. 18:1428–1439.

10. Shibata MA, Liu ML, Knudson MC, Shibata E, Yoshidome K, Bandey T, Korsmeyer SJ, Green JE. Haploid loss of bax leads to accelerated mammary tumor development in C3 (1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J. 1999. 18:2692–2701.

11. Knudson CM, Johnson GM, Lin Y, Korsmeyer SJ. Bax accelerates tumorigenesis in p53-deficient mice. Cancer Res. 2001. 61:659–665.

12. Eischen CM, Rehg JE, Korsmeyer SJ, Cleveland JL. Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice. Cancer Res. 2002. 62:2184–2191.

13. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R, Green DR, Newmeyer DD. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell. 2002. 111:331–342.

14. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB, Korsmeyer SJ. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 2000. 14:2060–2071.

15. Strasser A, Puthalakath H, Bouillet P, Huang DC, O'Connor L, O'Reilly LA, Cullen L, Cory S, Adams JM. The role of bim, a proapoptotic BH3-only member of the Bcl-2 family in cell-death control. Ann N Y Acad Sci. 2000. 917:541–548.

16. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005. 19:1294–1305.

17. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, Strasser A, Kluck RM, Adams JM, Huang DC. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science. 2007. 315:856–869.

18. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005. 17:393–403.

19. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004. 303:1010–1014.

20. Moll UM, Wolff S, Speidel D, Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol. 2005. 17:631–636.

21. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 1995. 55:4471–4478.

22. Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S. Prognostic significance of p53, Bcl-2, and Bax expression in early breast cancer. J Am Coll Surg. 2004. 198:83–90.

23. Baekelandt M, Holm R, Nesland JM, Trope CG, Kristensen GB. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J Clin Oncol. 2000. 18:3775–3781.

24. Kupryjanczyk J, Szymanska T, Madry R, Timorek A, Stelmachow J, Karpinska G, Rembiszewska A, Ziolkowska I, Kraszewska E, Debniak J, Emerich J, Ulanska M, Pluzanska A, Jedryka M, Goluda M, Chudecka-Glaz A, Rzepka-Gorska I, Klimek M, Urbanski K, Breborowicz J, Zielinski J, Markowska J. Evaluation of clinical significance of TP53, Bcl-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer. 2003. 88:848–854.

25. Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dorken B, Daniel PT. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol. 1999. 17:1364–1374.

26. Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Hass HG, Arkenau HT, Hartmann JT, Porschen R, Gregor M, Klump B. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer. 2007. 96:1409–1418.

27. Chang HJ, Jung KH, Kim DY, Jeong SY, Choi HS, Kim YH, Sohn DK, Yoo BC, Lim SB, Kim DH, Ahn JB, Kim IJ, Kim JM, Yoon WH, Park JG. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol. 2005. 36:364–371.

28. Xie X, Clausen OP, De Angelis P, Boysen M. Bax expression has prognostic significance that is enhanced when combined with AgNOR counts in glottic carcinomas. Br J Cancer. 1998. 78:100–105.

29. Ito T, Fujieda S, Tsuzuki H, Sunaga H, Fan G, Sugimoto C, Fukuda M, Saito H. Decreased expression of Bax is correlated with poor prognosis in oral and oropharyngeal carcinoma. Cancer Lett. 1999. 140:81–91.

30. Bandoh N, Hayashi T, Kishibe K, Takahara M, Imada M, Nonaka S, Harabuchi Y. Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma. Cancer. 2002. 94:1968–1980.

31. Kang SY, Oh YT, Han JH, Choi JH, Lim HY, Kim HI, Lee HW, Jang JH, Park JS, Kim HC, Kang S, Chun M, Kim CH, Joo HJ. Concurrent chemoradiotherapy in patients with nasopharyngeal cancer: prognostic significance of low expression of bax. Neoplasma. 2006. 53:450–456.

32. Sturm I, Petrowsky H, Volz R, Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dorken B, Daniel PT. Analysis of p53/BAX/p16 (ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol. 2001. 19:2272–2281.

33. Kang SY, Han JH, Lee KJ, Choi JH, Park JI, Kim HI, Lee HW, Jang JH, Park JS, Kim HC, Kang S, Oh YT, Chun M, Kim JH, Sheen SS, Lim HY. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res. 2007. 13:4146–4153.

TOOLS

Similar articles